2型糖尿病并发周围神经病理性疼痛的患病率及危险因素分析

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (732 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨住院患者2型糖尿病(type 2 diabetes mellitus,T2DM)并发周围神经病理性疼痛(diabetic peripheral neuropathic pain, DPNP)的患病率及危险因素。方法选取2020-10至2021-02山西医科大学附属第二医院T2DM周围神经病变的住院患者260例。根据神经病理性症状和体征评分(LANSS)问卷,≥12分诊断为DPNP,＜12分为非DPNP,将患者分为DPNP组(129例)和非DPNP组(131例)。比较两组的一般资料和实验室资料,将组间比较有意义的变量纳入二元Logistic回归分析。结果 DPNP组与非DPNP组一般资料比较,病程、合并糖尿病视网膜病变和合并糖尿病肾病差异有统计学意义(P<0.05),性别、年龄、BMI、吸烟史、饮酒史、家族史、学历、合并高血压、合并心血管疾病、用药情况、监测血糖情况、治疗方案、体重管理、饮食控制和身体活动差异无统计学意义。实验室资料比较,两组HbA₁c、HDL-C、尿微量白蛋白和UACR差异有统计学意义(P<0.05);空腹血糖及C肽、餐后2 h血糖及C肽、三酰甘油、总胆固醇、LDL-C、尿素、肌酐、尿酸和尿肌酐差异无统计学意义。二元Logistic回归分析得出,病程(OR=1.042,95%CI 1.001～1.085,P=0.045)、合并糖尿病肾病(OR=3.565,95%CI 1.497～8.487, P=0.004)、HbA₁c(OR=1.179,95%CI 1.041～1.334,P=0.009)、HDL-C(OR=0.228,95%CI 0.073～0.705,P=0.010)、UACR(OR=1.004,95%CI 1.001～1.008, P=0.027)是DPNP发生的危险因素。结论对于病程较长,合并糖尿病肾病、HbA₁c升高、HDL-C降低、UACR升高的患者,应警惕DPNP发生的风险。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨慧芳
	魏碧玉
	高明龙

关键词 ： 2型糖尿病, 糖尿病周围神经病理性疼痛, 患病率, 危险因素

Abstract：Objective To study the incidence and risk factors of diabetic peripheral neuropathic pain (DPNP) among inpatients with type 2 diabetes. Methods Two hundred and sixty patients with type 2 diabetic peripheral neuropathy were selected, and the basic information and laboratory data on these patients were collected. According to the Leeds Assessment of Neuropathic Symptoms and Signs(LANSS)questionnaire, a score ≥12 was diagnosed as DPNP, while a score of less than 12 was classified as non-DPNP. Patients were divided into the DPNP group (n=129) and non-DPNP group(n=131). The related data was compared between the two groups, and the significant variables between the groups were included in the binary logistic regression analysis. Statistical analysis showed that the course of disease, diabetic nephropathy, HbA₁c, low HDL-C, and UACR were risk factors for DPNP. Results There was statistically significant difference between the two groups in the course of disease and the incidence of complications with diabetic retinopathy and diabetic nephropathy (all P＜0.05), but not in gender, age, BMI, smoking history, drinking history, family history of disease, levels of education, complications with hypertension and cardiovascular diseases, medication, blood glucose monitoring, treatment plans, weight control, diet control or physical activity (all P＞0.05). Levels of HbA₁c, HDL-C, urinary microalbumin and UACR were statistically different between the two groups (all P＜0.05), but those of fasting blood glucose and C peptide, 2 h postprandial blood glucose and C peptide, triglycerides, total cholesterol, LDL-C, urea, creatinine, uric acid and urine creatinine were not (all P＞0.05). Binary Logistic regression analysis showed that the course of disease (OR=1.042, 95%CI 1.001-1.085, P=0.045), diabetic nephropathy (OR=3.565, 95%CI 1.497-8.487, P=0.004), HbA₁c (OR=1.179, 95%CI 1.041-1.334, P=0.009), HDL-C (OR=0.228, 95%CI 0.073-0.705, P=0.010)and UACR (OR=1.004, 95%CI 1.001-1.008, P=0.027) were risk factors for DPNP. Conclusions Patients with a longer clinical course, diabetic nephropathy, increased HbA₁c, decreased HDL-C, and increased UACR are at high risk of diabetic peripheral neuropathic pain.

Key words： type 2 diabetes mellitus diabetic peripheral neuropathic pain incidence risk factors

收稿日期: 2021-02-01

ZTFLH:

R614

通讯作者: 高明龙,E-mail:gaominglongg@163.com

作者简介: 杨慧芳,硕士研究生,住院医师。

引用本文:

杨慧芳, 魏碧玉, 高明龙. 2型糖尿病并发周围神经病理性疼痛的患病率及危险因素分析[J]. 武警医学, 2021, 32(7): 562-567. YANG Huifang, WEI Biyu, GAO Minglong. Incidence and risk factors of type 2 diabetes complicated by peripheral neuropathic pain among inpatients. Med. J. Chin. Peop. Armed Poli. Forc., 2021, 32(7): 562-567.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2021/V32/I7/562

[1]	Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy[J].Clin Ther, 2018, 40(6): 828-849.
[2]	Tesfaye S, Boulton A J, Dyck P J, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments[J] .Diabetes Care, 2010, 33(10): 2285-2293.
[3]	Bohlega S, Alsaadi T, Amir A,et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the Middle East region[J]. J Int Med Res,2010,38(2):295-317.
[4]	Busui R, Boulton A J, Feldman E L, et al. Diabetic neuropathy: a position statement by the American diabetes association[J].Diabetes Care, 2017, 40(1): 136-154.
[5]	Vileikyte L,Peyrot M,Gonzalez J S,et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study[J].Diabetologia, 2009, 52(7): 1265-1273.
[6]	Sadosky A, Schaefer C, Mann R,et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey[J].Diabetes Metab Syndr Obes, 2013, 6: 79-92.
[7]	Ziegler D, Landgraf R, Lobmann R, et al. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (protect study)[J]. Diabetes Res Clin Pract,2018,139(2): 147-154.
[8]	Abbott C A, Malik R A, Ross E R, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK[J]. Diabetes Care, 2011, 34(10):2220-2224.
[9]	Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study[J]. PLoS One, 2013, 8(9): e74195.
[10]	Liu Xiuxiu, Xu Yuyan, An Miaomiao,et al. The risk factors for diabetic peripheral neuropathy: a meta-analysis[J] .PLoS One, 2019, 14(2): e0212574.
[11]	Unal C I,Sarioglu A S,Evcik D. A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4[J].J Pain, 2010, 11(11): 1129-1135.
[12]	Ponirakis G,Elhadd T,Chinnaiyan S,et al. Prevalence and risk factors for diabetic neuropathy and painful diabetic neuropathy in primary and secondary healthcare in Qatar[J].J Diabetes Investig, 2019,10(6) : 1556-1564.
[13]	Rosenberger D C,Blechschmidt V,Timmerman H,et al. Challenges of neuropathic pain: focus on diabetic neuropathy[J] .J Neural Transm, 2020, 127(26): 589-624.
[14]	Acker K, Bouhassira D, Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics[J]. Diabetes Metab,2009, 35(3): 206-213.
[15]	Jambart S, Ammache Z, Haddad F, et al. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region[J]. J Int Med Res,2011, 39(2): 366-377.
[16]	Halawa M R, Karawagh A, Zeidan A, et al. Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia[J]. Curr Med Res Opin,2010, 26(2): 337-343.
[17]	Cole B E. Diabetic peripheral neuropathic pain: recognition and management[J]. Pain Med, 2007,8:S27-32.
[18]	Huang C,Chen T,Weng M, et al. Effect of glycemic control on electrophysiologic changes of diabetic neuropathy in type 2 diabetic patients[J] .Kaohsiung J Med Sci, 2005, 21(1): 15-21.
[19]	Alkhatatbeh M, Razzak K K. Neuropathic pain is not associated with serum vitamin D but is associated with female gender in patients with type 2 diabetes mellitus[J]. BMJ Open Diabetes Res Care, 2019, 7(1):e000690.
[20]	Tesfaye S,Vileikyte L,Rayman G,et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management[J] .Diabetes Metab Res Rev, 2011, 27(7): 629-638.
[21]	Weng Y,Tsai S,Lyu R,et al. Diabetic distal symmetrical polyneuropathy: correlation of clinical, laboratory, and electrophysiologic studies in patients with type 2 diabetes mellitus[J] .J Diabetes Res, 2020,(28):6356459.
[22]	John D, Thomas L E, Szuhuei W,et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy[J] .J Clin Endocrinol Metab, 2009, 94(6): 2157-2163.
[23]	Bansal D, Gudala K, Muthyala H, et al. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting[J]. J Diabetes Investig, 2014 ,5(6):714-721.
[24]	Kamenov Z A, Parapunova R A, Georgieva R T. Earlier development of diabetic neuropathy in men than in women with type 2 diabetes mellitus[J].Gend Med,2010, 7(6):600-615.
[25]	Ziegler D, Landgraf R, Lobmann R, et al.Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (protect study)[J].Diabetes Res Clin Pract,2018, 139(5): 147-154.
[26]	Aslam A, Singh J, Rajbhandari S. Prevalence of painful diabetic neuropathy using the self-completed leeds assessment of neuropathic symptoms and signs questionnaire in a population with diabetes[J]. Can J Diabetes 2015, 39(4):285-295.
[27]	Amato C,Morganti R,Greco C,et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities[J].Diab Vasc Dis Res, 2016, 13(6): 418-428.
[28]	Pai Y,Lin C,Lee I,et al. Prevalence and biochemical risk factors of diabetic peripheral neuropathy with or without neuropathic pain in Taiwanese adults with type 2 diabetes mellitus[J] .Diabetes Metab Syndr, 2018, 12(2): 111-116.